Edition:
United States

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

21.82EUR
15 Dec 2017
Change (% chg)

€0.06 (+0.28%)
Prev Close
€21.76
Open
€21.83
Day's High
€22.04
Day's Low
€21.73
Volume
90,382
Avg. Vol
150,945
52-wk High
€35.65
52-wk Low
€20.11

Latest Key Developments (Source: Significant Developments)

Genfit announces positive outcome of DSMB safety review
Wednesday, 22 Nov 2017 12:18pm EST 

Nov 22 (Reuters) - GENFIT SA ::REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR.‍SAFETY DATA REVIEWED BY DSMB WHICH RECOMMENDED CONTINUATION OF TRIAL WITHOUT ANY MODIFICATIONS​.‍POSITIVE OUTCOME OF REVIEW ALLOWS GENFIT TO ACTIVELY PURSUE ITS EFFORT IN ENROLLING PATIENTS AND CONTINUATION OF RESOLVE-IT TRIAL​.‍POSITIVE OUTCOME CONFIRMS GOOD SAFETY PROFILE OF ELAFIBRANOR​.  Full Article

Genfit completes offering of convertible bonds due 2022 for 180 million euros
Tuesday, 17 Oct 2017 02:30am EDT 

Oct 17 (Reuters) - GENFIT SA ::REG-GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022.‍OFFERING WAS MULTIPLE TIMES OVERSCRIBED, INITIAL AMOUNT OF OFFERING WAS INCREASED FROM EUR 150 MILLION TO EUR 180 MILLION​.NOMINAL UNIT VALUE OF THE OCEANES WAS SET AT €29.60, REPRESENTING A CONVERSION/EXCHANGE PREMIUM OF 30% TO CO’S REFERENCE SHARE PRICE‍​.‍OCEANES BEAR INTEREST AT AN ANNUAL NOMINAL RATE OF 3.50% PAYABLE SEMI-ANNUALLY IN ARREARS ON APRIL 16, AND OCT 16 OF EACH YEAR​.  Full Article

Genfit completes convertible bonds offering for amount of 180 million euros
Wednesday, 11 Oct 2017 08:20am EDT 

Oct 11 (Reuters) - GENFIT SA ::REG-GENFIT ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF €180 MILLION.‍INITIAL AMOUNT OF EUR 150 MILLION HAS BEEN INCREASED TO EUR 180 MILLION IN ACCORDANCE WITH CORPORATE AUTHORIZATIONS OF COMPANY​.  Full Article

Genfit launches an offering of conbertible bonds for around 150 million euros
Wednesday, 11 Oct 2017 01:33am EDT 

Oct 11 (Reuters) - GENFIT SA ::GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION.‍OCEANES WILL BEAR INTEREST AT AN ANNUAL NOMINAL RATE COMPRISED BETWEEN 3.00% AND 3.50% PAYABLE SEMI-ANNUALLY​.‍NOMINAL UNIT VALUE OF OCEANES WILL BE SET AT A CONVERSION/EXCHANGE PREMIUM OF BETWEEN 30% AND 35% TO GENFIT'S REFERENCE SHARE PRICE​.BONDS TO BE REDEEMED AT PAR ON OCT 16, 2022.‍​.  Full Article

Genfit reports‍ nine months revenues at 91 thousand euros
Wednesday, 11 Oct 2017 01:31am EDT 

Oct 11 (Reuters) - GENFIT SA : :‍CASH AND CASH EQUIVALENTS OF EUR 113.8 MILLION AT SEPTEMBER 30, 2017​.‍REVENUES FOR FIRST NINE MONTHS OF 2017 OF EUR 91 THOUSAND​.  Full Article

Genfit H1 operating loss widens to 22.4 million euros
Monday, 25 Sep 2017 12:09pm EDT 

Sept 25 (Reuters) - GENFIT SA ::REG-GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE.H1 NET LOSS EUR ‍​22.6 MILLION VERSUS LOSS OF EUR 12.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 22.4 MILLION VERSUS LOSS OF EUR 12.8 MILLION YEAR AGO.H1 REVENUE EUR 4.7 MILLION VERSUS EUR 3.6 MILLION YEAR AGO.BY END OF YEAR, EXPECTS TO HAVE FILED APPLICATION FOR AUTHORIZATION TO LAUNCH PHASE 2 TRIAL TO EVALUATE EFFICACY OF NITAZOXANIDE IN LIVER FIBROSIS​.EXPECTS RESEARCH AND DEVELOPMENT COSTS TO CONTINUE TO INCREASE IN H2 2017.EXPECTS TO SIGN NEW COLLABORATIONS FOR FURTHER VALIDATION OF GENFIT DIAGNOSTIC TEST.PLANS TO SUBMIT TO FDA APPLICATION FOR AUTHORIZATION TO LAUNCH FIRST PROOF-OF-CONCEPT PHASE 2 STUDY OF NITAZOXANIDE IN NASH PATIENTS WITH ADVANCED FIBROSIS, BEFORE END OF YEAR.  Full Article

Genfit cash and cash equivalents at March 31 rises to 137.0 million euros
Monday, 24 Apr 2017 02:30am EDT 

April 24 (Reuters) - Genfit SA ::Q1 revenue 26,000 euros ($28,176.20) versus 88,000 euros year ago.Cash and cash equivalents at March 31 137.0 million euros versus 102.8 million euros year ago.Phase 2A clinical trial of Elafibranor is entering its active enrollment phase.  Full Article

Shares in pharma company Genfit surge for second day in row
Tuesday, 14 Mar 2017 04:16am EDT 

Genfit : Shares up around 5 pct, building on 13.4 percent gain on March 13 . Genfit, which specializes in the development of medicines for the prevention and treatment of diabetes and related disorders, has declined to comment on reports that it is a takeover target [nL5N1GQ5PZ] . Previous reports have mentioned Novartis as being interested in buying Genfit [nL5N1GF5CA] Further company coverage: [GNFT.PA] ((sudip.kargupta@thomsonreuters.com;)).  Full Article

French drugmaker Genfit said to explore options including sale - Bloomberg, citing sources
Monday, 5 Dec 2016 03:08pm EST 

: French drugmaker Genfit said to explore options including sale - Bloomberg, citing sources .Genfit is also weighing licensing agreements, partnerships or joint ventures - Bloomberg citing a source.  Full Article

Genfit cash and cash equivalents of EUR 84.86 million at Sept. 30, 2016
Tuesday, 8 Nov 2016 02:30am EST 

Genfit Sa : Cash and cash equivalents of 84.86 million euros ($93.75 million) as at September 30, 2016 .Revenues for first nine months of 2016 amount to 0.22 million euros compared to 0.45 million euros for same period in 2015.  Full Article

BRIEF-Genfit announces positive outcome of DSMB safety review

* REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR